TY  - JOUR
A1  - Bojkova, Denisa
A1  - Zöller, Nadja Nicole
A1  - Tietgen, Manuela
A1  - Steinhorst, Katja
A1  - Bechtel, Marco
A1  - Rothenburger, Tamara
A1  - Kandler, Joshua D.
A1  - Schneider, Julia
A1  - Corman, Victor Max
A1  - Ciesek, Sandra
A1  - Rabenau, Holger
A1  - Wass, Mark N.
A1  - Kippenberger, Stefan
A1  - Göttig, Stephan
A1  - Michaelis, Martin
A1  - Cinatl, Jindrich
T1  - Repurposing of the antibiotic nitroxoline for the treatment of mpox
T2  - Journal of Medical Virology
N2  - The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited availability (tecovirimat), and potentially by resistance formation. Hence, additional, readily available drugs are needed. Here, therapeutic concentrations of nitroxoline, a hydroxyquinoline antibiotic with a favourable safety profile in humans, inhibited the replication of 12 mpox virus isolates from the current outbreak in primary cultures of human keratinocytes and fibroblasts and a skin explant model by interference with host cell signalling. Tecovirimat, but not nitroxoline, treatment resulted in rapid resistance development. Nitroxoline remained effective against the tecovirimat-resistant strain and increased the anti-mpox virus activity of tecovirimat and brincidofovir. Moreover, nitroxoline inhibited bacterial and viral pathogens that are often co-transmitted with mpox. In conclusion, nitroxoline is a repurposing candidate for the treatment of mpox due to both antiviral and antimicrobial activity.
KW  - antiviral drugs
KW  - antiviral therapy
KW  - chelator
KW  - drug repurposing
KW  - monkeypox
KW  - orthopoxvirus
KW  - poxvirus
Y1  - 2023
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75062
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-750623
SN  - 1096-9071
SN  - 0146-6615
VL  - 95
IS  - 3, e28652
PB  - Wiley
CY  - Bognor Regis [u.a.]
ER  -